Overview

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept